DOI QR코드

DOI QR Code

Methylation Status and Expression of BRCA2 in Epithelial Ovarian Cancers in Indonesia

  • Pradjatmo, Heru (Obstetrics and Gynecology Department, Universitas Gadjah Mada-Sardjito Central Hospital)
  • Published : 2016.01.11

Abstract

Ovarian cancer is the main cause of mortality in gynecological malignancy and extensive studies have been conducted to study the underlying molecular mechanisms. The BRCA2 gene is known to be an important tumor suppressor in ovarian cancer, thereby BRCA2 alterations may lead to cancer progression. However, the BRCA2 gene is rarely mutated, and loss of function is suspected to be mediated by epigenetic regulation. In this study we investigated the methylation status and gene expression of BRCA2 in ovarian cancer patients. Ovarian cancer pateints (n=69) were recruited and monitored for 54 months in this prospective cohort study. Clinical specimens were used to study the in situ expression of aberrant BRCA2 proteins and the methylation status of BRCA2. These parameters were then compared with clinical parameters and overall survival rate. We found that BRCA2 methylation was found in the majority of cases (98.7%). However, the methylation status was not associated with protein level expression of BRCA2 (49.3%). Therefore in addition to DNA methylation, other epigenetic mechanisms may regulate BRCA2 expresison. Our findings may become evidence of BRCA2 inactivation mechanism through DNA methylation in the Indonesian population. More importantly, from multivariate analysis, BRCA2 expression was correlated with better overall survival (HR 0.32; p=0.05). High percentage of BRCA2 methylation and correlation of BRCA2 expression with overall survival in epithelial ovarian cancer cases may lead to development of treatment modalities specifically to target methylation of BRCA genes.

Keywords

BRCA2;epigenetic;methylation;epithelial ovarian cancer;survival

References

  1. Li SD, Zhang JR,Wang YQ,Wan XP 2010. The role of microRNAs in ovarian cancer initiation and progression. J Cell Mol Med, 14, 2240-49. https://doi.org/10.1111/j.1582-4934.2010.01058.x
  2. McCabe N, Turner NC, Lord CJ, et al (2006). Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res, 66, 8109-15. https://doi.org/10.1158/0008-5472.CAN-06-0140
  3. Meetei AR, Levitus M, Xue Y, et al (2004). X-linked inheritance of Fanconi anemia complementation group B. Nature Genetics, 36, 1219-24. https://doi.org/10.1038/ng1458
  4. Olek A, Oswald J, Walter J (1996). A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res, 24, 5064-6. https://doi.org/10.1093/nar/24.24.5064
  5. Pradjatmo H, Dasuki D, Anwar M, Mubarika S, Harijadi (2014). Methylation status and immunohistochemistry of BRCA1 in epithelial ovarian cancer. Asian Pac J Cancer Prev, 15, 9479-85. https://doi.org/10.7314/APJCP.2014.15.21.9479
  6. Rathi A, Virmani AK, Schorge JO, et al (2002). Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res, 8, 3324-31.
  7. Shabanizadeh A, Dahim H, Salahshoor R, et al (2013). Promoter methylation status and protein expression of BRCA2 in patients with epithelial ovarian cancer. Middle East Journal of Cancer, 4, 15-20.
  8. Thrall M, Gallion HH, Kryscio R, et al (2006). BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Inter J of Gynecol Cancer, 16, 166-71. https://doi.org/10.1111/j.1525-1438.2006.00504.x
  9. Venkitaraman AR (2002). Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell, 108, 171-82. https://doi.org/10.1016/S0092-8674(02)00615-3
  10. Laird PW (2003). The power and the promise of DNA methylation markers. Nat Rev Cancer, 3, 253-66. https://doi.org/10.1038/nrc1045
  11. Lesnock JL, Darcy KM, Tian C, et al (2013). BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. British J Cancer, 108, 1231-7. https://doi.org/10.1038/bjc.2013.70
  12. Catteau A, Harris WH, Xu CF, Solomon E (1999). Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene, 18, 1957-65. https://doi.org/10.1038/sj.onc.1202509
  13. Chan KY, Ozcelik H, Cheung AN, Ngan HY, Khoo US (2002). Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res, 62, 4151- 56.
  14. Darehdori AS, Dastjerdi MN, Dahim H, et al (2012). Lack of significance of the BRCA2 promoter methylation status in Different Genotypes of the MTHFR a1298c polymorphism in ovarian cancer cases in Iran. Asian Pac J Cancer Prev, 13, 1833-6. https://doi.org/10.7314/APJCP.2012.13.5.1833
  15. Dhillon VS, Shahid M, Husain SA (2004). CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin. Mol Cancer, 3, 1-8. https://doi.org/10.1186/1476-4598-3-1
  16. Gudmundsdottir K, Ashworth A (2006). The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene, 25, 5864-74. https://doi.org/10.1038/sj.onc.1209874
  17. Hedenfalk I, Duggan D, Chen Y, et al (2001). Gene-expression profiles in hereditary breast cancer. The New Eng J of Med, 344, 539-48. https://doi.org/10.1056/NEJM200102223440801
  18. Herman JG, Baylin SB, (2003). Gene silencing in cancer in association with promoter hypermethylation. The New Engl J of Medicine, 349, 2042-54. https://doi.org/10.1056/NEJMra023075
  19. Hilton JL, Geisler JP, Rathe JA, et al (2002). Inactivation of BRCA1 and BRCA2 in Ovarian Cancer. J Natl Cancer Inst, 94, 1396-406. https://doi.org/10.1093/jnci/94.18.1396
  20. Holschneider CH, Berek JS (2000). Ovarian cancer: epidemiology, biology, and prognostic factors. Seminars in Surgical Oncology, 19, 3-10. https://doi.org/10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S
  21. Jones PA (1996). DNA methylation errors and cancer. Cancer Res, 56, 2463-7.
  22. Kontorovich T, Cohen Y, Nir U, Friedman E (2009). Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers. Breast Cancer Res Treat, 116, 195-200. https://doi.org/10.1007/s10549-008-0121-3
  23. Korstanje R, Albers JJ, Wolfbauer G, et al (2004). Quantitative trait locus mapping of genes that regulate phospholipid transfer activity in SM/J and NZB/BlNJ inbred mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 155-60. https://doi.org/10.1161/01.ATV.0000104241.44819.10
  24. An J, Wei Q, Liu Z et al (2010). Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis. Inter J of Mol Epid and Gen, 1, 1-10.
  25. Baldwin RL, Nemeth E, Tran H, et al (2000). BRCA1 promoter region hypermethylation in ovarian carcinoma: a populationbased study. Cancer Res, 60, 5329-33.
  26. Bosviel R, Michard E, Lavediaux G, et al (2011). Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls. Clinica Chimica acta. Inter J of Clin Chem, 412, 1472-5.
  27. Yanagawa N, Tamura G, Honda T, et al (2004). Demethylation of the synuclein gamma gene CpG island in primary gastric cancers and gastric cancer cell lines. Clin Cancer Res, 10, 2447-51. https://doi.org/10.1158/1078-0432.CCR-03-0107

Cited by

  1. SET and MYND Domain-Containing Protein 3 (SMYD3) Polymorphism as a Risk Factor for Susceptibility and Poor Prognosis in Ovarian Cancer vol.22, pp.1643-3750, 2016, https://doi.org/10.12659/MSM.898095
  2. A novel loss-of-function heterozygous BRCA2 c.8946_8947delAG mutation found in a Chinese woman with family history of breast cancer vol.143, pp.4, 2017, https://doi.org/10.1007/s00432-016-2327-9